- Home
- AMRN vs MREO Comparison
AMRN vs MREO Comparison
Compare AMRN & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- MREO
- Stock Information
- Founded
- AMRN 1989
- MREO 2015
- Country
- AMRN Ireland
- MREO United Kingdom
- Employees
- AMRN N/A
- MREO N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- AMRN Health Care
- MREO Health Care
- Exchange
- AMRN Nasdaq
- MREO Nasdaq
- Market Cap
- AMRN 317.1M
- MREO 281.6M
- IPO Year
- AMRN 1993
- MREO N/A
- Fundamental
- Price
- AMRN $15.01
- MREO $1.85
- Analyst Decision
- AMRN Strong Sell
- MREO Strong Buy
- Analyst Count
- AMRN 1
- MREO 5
- Target Price
- AMRN $12.00
- MREO $7.40
- AVG Volume (30 Days)
- AMRN 55.2K
- MREO 935.5K
- Earning Date
- AMRN 10-29-2025
- MREO 11-11-2025
- Dividend Yield
- AMRN N/A
- MREO N/A
- EPS Growth
- AMRN N/A
- MREO N/A
- EPS
- AMRN N/A
- MREO N/A
- Revenue
- AMRN $219,361,000.00
- MREO $500,000.00
- Revenue This Year
- AMRN N/A
- MREO N/A
- Revenue Next Year
- AMRN N/A
- MREO $55.50
- P/E Ratio
- AMRN N/A
- MREO N/A
- Revenue Growth
- AMRN N/A
- MREO N/A
- 52 Week Low
- AMRN $7.08
- MREO $1.47
- 52 Week High
- AMRN $17.49
- MREO $4.72
- Technical
- Relative Strength Index (RSI)
- AMRN 46.36
- MREO 57.48
- Support Level
- AMRN $14.80
- MREO $1.68
- Resistance Level
- AMRN $15.46
- MREO $1.83
- Average True Range (ATR)
- AMRN 0.50
- MREO 0.07
- MACD
- AMRN -0.05
- MREO 0.02
- Stochastic Oscillator
- AMRN 27.74
- MREO 90.48
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).